Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endocrine dysfunction in adrenoleukodystrophy.

Handbook of clinical neurology - 1 Jan 2021

Engelen Marc, Kemp Stephan, Eichler Florian

Abstract excerpt

X-linked adrenoleukodystrophy (ALD) is a peroxisomal disorder caused by mutations in the ABCD1 gene and characterized by impaired very long-chain fatty acid beta-oxidation. Clinically, male patients develop adrenal failure and a progressive myelopathy in adulthood, although age of onset and rate of progression are highly variable. Additionally, 40% of male patients develop a leukodystrophy (cerebral ALD) before...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Adrenoleukodystrophy
Share to Fatty Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Spinal Cord Diseases

Source

Identifiers

PMID: 34266597
DOI: 10.1016/B978-0-12-819973-2.00018-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endocrine dysfunction in adrenoleukodystrophy.PMID 34266597Read ↗

Endocrine Dysfunction in X-Linked Adrenoleukodystrophy.Semantic proximity Read ↗

X-linked adrenoleukodystrophy: pathogenesis and treatment.Semantic proximity Read ↗

X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.Semantic proximity Read ↗

Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies.Semantic proximity Read ↗

Evolution of adrenoleukodystrophy model systems.Semantic proximity Read ↗

X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects.Semantic proximity Read ↗

Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapiesSemantic proximity Read ↗

X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects.Semantic proximity Read ↗

From gene to therapy: a review of deciphering the role of ABCD1 in combating X-Linked adrenoleukodystrophy.Semantic proximity Read ↗

X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.Semantic proximity Read ↗

[X-linked adrenoleukodystrophy].Semantic proximity Read ↗

The clinical spectrum of X-linked adrenoleukodystrophy: from Addison's-only in men to middle-age neurologic manifestations in women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.